In this episode, Prof. Scott Tagawa (US), a medical oncologist at Weill Cornell Medicine in New York, discusses the results of PSMAddition - a phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. This interview was recorded at ESMO 2025 in Berlin, Germany. For more updates on prostate cancer, please visit our educational platform UROONCO PCa . For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts , Spotify , EAU YouTube channel .
